Expansion opportunities FutureMeds is actively expanding its European footprint with new facilities in Düsseldorf and broader Germany expansion planned for November 2026, presenting a sales opportunity to discuss site network scalability, local regulatory support, and faster trial activation for sponsors running trials in Western Europe.

Strategic partnerships Recent collaboration with HabCare CRO signals a openness to co-deliver de-risked trial delivery and enhanced participant experience, suggesting potential in joint bids, expanded DCT capabilities, and shared access to patient-centric operational models for sponsors seeking risk mitigation.

DCT and patient engagement With a patient-centric focus, broad site and homecare provider network, and involvement in conferences on data AI and patient engagement, there is a clear opportunity to position FutureMeds as a preferred partner for adaptive DCT strategies and real-world data collection to accelerate patient access.

Leadership visibility CEO recognition in EY Entrepreneur of the Year UK and strategic leadership hires such as a Chief People Officer indicate a growth-oriented, governance-conscious organization, which can be leveraged to position FutureMeds as a stable, scalable partner for large sponsors seeking reliable execution and strong people processes.

Market positioning A European, independent site network with over 29 sites and 220 investigators across multiple therapeutic areas offers competitive advantages for sponsors prioritizing diverse regional access, speed to site initiation, and robust data quality across DCT-enabled trials in Western Europe.